Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

Research area

Phase 3 Pancreatic Cancer trials

You will find pancreatic cancer studies here that are in Phase 3, including combined Phase 2/3. If you want to know whether one may be a fit, Phase 3 Cancer Trials can help you find out.

Updated

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Phase 3 pancreatic cancer studies in numbers

Phase 3 pancreatic cancer studies recruiting in the U.S.
22
states with a study site
51

Source: ClinicalTrials.gov. Data processed .

Find Phase 3 pancreatic cancer studies by state

These states have the most studies recruiting right now.

Phase 3 pancreatic cancer studies recruiting now

As of November 18, 2026, 22 Phase 3 pancreatic cancer studies are recruiting participants in the United States, according to ClinicalTrials.gov. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry. This is what they have in common.

What they test

  • medications19
  • other approaches5
  • procedures3
  • biologics such as vaccines or antibodies2
  • radiation2

A study can test more than one.

Main purpose

  • treating a condition17
  • diagnosis2
  • prevention2
  • supportive care1

Phase

  • Phase 2/35
  • Phase 317

Who runs them

  • industry15
  • university, hospital or other7

Who they enroll

  • adults (18 to 64)22
  • older adults (65 and over)22

These counts come from each study's public record and change as studies open and close. Browse every location to see what is recruiting near you.

Source: ClinicalTrials.gov. Data processed . Each bar shows a count as a share of all 22 studies.

Recently updated Phase 3 pancreatic cancer studies

The 6 studies whose public records changed most recently, with some of the places each is recruiting. Select a study to read its full record on ClinicalTrials.gov.

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Recruiting in
    Anchorage, AK · Ann Arbor, MI · Atlanta, GA · and 43 more U.S. locations
    Registry record
    NCT07522073 · updated
  2. Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Recruiting in
    Allentown, PA · Bethlehem, PA · Chicago, IL · and 13 more U.S. locations
    Registry record
    NCT06807437 · updated
  3. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immuneering Corporation
    Recruiting in
    Abilene, TX · Arlington Heights, IL · Atlanta, GA · and 40 more U.S. locations
    Registry record
    NCT07562152 · updated
  4. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Recruiting in
    Atlanta, GA · Baltimore, MD · Boston, MA · and 14 more U.S. locations
    Registry record
    NCT07621718 · updated
  5. Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Recruiting in
    Jacksonville, FL · Phoenix, AZ · Providence, RI · and 3 more U.S. locations
    Registry record
    NCT07805954 · updated
  6. A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Recruiting in
    Ann Arbor, MI · Atlanta, GA · Baltimore, MD · and 47 more U.S. locations
    Registry record
    NCT07409272 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in the United States on ClinicalTrials.gov.

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and some of the places it is recruiting) exactly as registered. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

What Phase 3 pancreatic cancer studies look at

Here you will find pancreatic cancer studies in Phase 3, including combined Phase 2/3. Every one of them is built around a single question. Your part in a trial therefore depends on which one you are considering.

Nothing under study in these trials has moved past investigational status. Researchers have not yet settled what it can do or which risks come with it. Answering that is why each trial exists.

Who may be able to take part

Who can join depends on the trial, because each Phase 3 cancer study sets its own requirements. Those may cover your age and your health history. Medications you take now can matter, as can how the cancer affects you. Some trials enroll people without the condition as well.

You do not have to judge any of this yourself. During a screening visit, the study team confirms whether you meet the requirements. See how eligibility and screening work.

What taking part usually involves

  1. A first conversation

    Nothing else happens until you have spoken with a coordinator. They describe the Phase 3 study in broad terms. They also answer whatever you want to ask.

  2. Informed consent

    The complete details come to you as a written document, known risks included. The study team provides it. Whether you agree is up to you.

  3. Screening

    Screening checks whether a Phase 3 pancreatic cancer trial suits you. It involves questions about your health, along with some tests. Some people who go through screening do not go on to join the trial.

  4. Study visits

    Should you join the Phase 3 study, your visits happen on a set schedule. The team uses each one to keep track of your health. Leaving is your choice, whenever you wish.

Questions about Phase 3 pancreatic cancer studies

Do I need a diagnosis to join a study about pancreatic cancer?

Not always, since each trial sets this for itself. Certain studies want a diagnosis that is already confirmed. Others assess you as part of screening. Ask the study team and they will tell you which applies.

Would I have to change the care I receive now?

Whether your current care can continue is set by each trial. Some permit it. Others do not. Either way, changing care by yourself is not the right step. The study doctor will review this point with you, and your own doctor can talk it through with you before any decision.

Is there a cost to take part?

Taking part generally costs you nothing. That covers study visits, study tests and the study medication. Learn more about costs.

Ask about Phase 3 pancreatic cancer studies

Tell us a little about yourself, and expect to hear from a coordinator. An enquiry about a Phase 3 cancer trial is only a question. It leaves you free of any obligation.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Independent information

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call